Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human CapitalGlobeNewsWire • Wednesday
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024GlobeNewsWire • 07/19/24
Royalty Pharma (RPRX) Recently Broke Out Above the 50-Day Moving AverageZacks Investment Research • 07/17/24
Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 07/15/24
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024InvestorPlace • 06/26/24
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend YieldsBenzinga • 06/12/24
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceGlobeNewsWire • 06/04/24
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 MillionGlobeNewsWire • 05/28/24
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D PipelineGlobeNewsWire • 05/22/24
Royalty Pharma (RPRX) Q1 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 05/09/24
Insights Into Royalty Pharma (RPRX) Q1: Wall Street Projections for Key MetricsZacks Investment Research • 05/06/24
Royalty Pharma (RPRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseZacks Investment Research • 05/02/24
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024GlobeNewsWire • 04/19/24